Supplements
Supplement: Current and Emerging Treatment Approaches Addess Unmet Needs in Glaucoma Care
Sustained-release implants and micro- or minimally invasive glaucoma surgeries (MIGS) are emerging therapies that address key unmet needs in glaucoma treatment. By broadening the spectrum of interventions, these therapies allow glaucoma specialists to consider more measured approaches earlier in disease progression, with a view to delay as well as safeguard the possibility of further invasive surgeries. Drs. Herbert Reitsamer, Andrew Tatham, and Iqbal Ike K. Ahmed discuss how patient compliance impacts glaucoma progression, the role of sustained-release drug delivery and MIGS in alleviating patient treatment burden, the use of MIGS in combination with cataract surgery, and how these therapies can be incorporated into the treatment paradigm.
Tags: glaucoma
Latest Articles
A New High for Hyperopia
Hyperopia patients can expect a rise in the array of treatments.
Research Committee is Engine Driving the Future of ESCRS
Commitment to evidence-based medicine anchors studies and other projects.
ESCRS EPICAT Study Updates
Early results suggest subconjunctival 10 mg triamcinolone an effective strategy for dropless cataract surgery.
Second Global Consensus on Keratoconus
Forthcoming position paper to provide an updated and expanded view on evaluation and management.
Automating Cataract Surgery Assessment
AI system measures eye stability and centration in procedures.
Post-LASIK Tonometer Takes ESCRS Innovators Den Prize
Good ideas lead to solutions to unmet needs.
ESCRS forms Functional Vision Working Group
Expanding the Limits of KLEx
Hyperopia treatment receives CE approval; mixed astigmatism may follow.